The decision comes months after the Supreme Court dismissed a similar challenge to the drug’s accessibility. The lawsuit, initially brought by a group of anti-abortion activists and doctors, was dismissed in 2024.
The court ruled that the plaintiffs lacked standing to challenge the FDA’s regulatory actions on mifepristone, as they failed to demonstrate personal harm from its distribution. However, U.S. District Judge Matthew Kacsmaryk on Jan. 16 ruled that Idaho, Missouri and Kansas can intervene and file the complaint.
The three states argue that the FDA’s approval of mifepristone for use up to 10 weeks of pregnancy, along with its availability via telemedicine and mail, has contributed to what they view as a public health risk.
The Justice Department previously sought to have the case dismissed, contending that the states lack legal standing to file the case in Texas. However, Mr. Kacsmaryk, who previously ruled in 2023 against the FDA and called for mifepristone’s removal from the market, disagreed with the Justice Department’s argument.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.